stent-related symptoms
Conditions
Interventions
Group 1:none
Group 2:mirabegron 50mg
Group 3:mirabegron50mg + tamsulosin0.2mg
Group 4:mirabegron 50mg + Yinhuamiyanling 2g
Sponsors
Qingdao Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria were acute benign ureteral obstruction or unilateral temporary stent placement after diagnosis/treatment of upper urinary tract.
Exclusion criteria
Exclusion criteria: 1) under the history, or the current treatment of urinary tract symptoms, chronic bacterial prostatitis, chronic pelvic pain syndrome and the male prostate cancer; 2) pressure/request/mixed urinary incontinence, urinary dysfunction and chronic ureteral obstruction, pregnant women; 3) obstruction due to malignancy, coagulant function abnormality, the history of bladder cancer, recurrent urinary tract infections overactive bladder syndrome, neurological and psychiatric diseases and receptor blockers anticholinergic drugs. We also excluded complex ureteroscopy, defined as: 1) mucosal injury edema or perforation; 2) multiple lesions larger than 2 cm or impacted stones; 3) stenosis; 4) surgical duration exceeding 30 minutes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ureteral stent symptom questionaire; | — |
Countries
China
Contacts
Public ContactZhu Changming
Qingdao Hospital of Traditional Chinese Medicine
Outcome results
None listed